Non-invasive monitoring of phenytoin by reverse iontophoresis

European Journal of Pharmaceutical Sciences

Volumn 22, Issue 5, 2004, Pages 427-433

  Leboulanger, Benoît ^a,b   Guy, Richard H ^a,b   Delgado Charro, M Begoña ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Centre Interuniversitaire de Recherche et d'Enseignement   (France)

Author keywords

Drug monitoring; Iontophoresis; Phenytoin; Transdermal

Indexed keywords

PHENYTOIN; VALPROIC ACID;

ANIMAL TISSUE; ARTICLE; CALIBRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ISOLATION; DRUG MONITORING; IONTOPHORESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SAMPLING; STEADY STATE;

ANIMALS; IONTOPHORESIS; PHENYTOIN; SKIN; SWINE;

EID: 3242722019     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2004.04.010     Document Type: Article

References (28)

1. Barre J., Didey F., Delion F., Tillement J.P. Problems in therapeutic drug monitoring: free drug level monitoring. Ther. Drug Monit. 10:1988;133-143
2. Bazil C.W., Pedley T.A. Advances in the medical treatment of epilepsy. Annu. Rev. Med. 49:1998;135-162
3. Beringer P.M., Rho J.P. Is routine measurement of free phenytoin concentrations rational? Ther. Drug Monit. 17:1995;381-382
4. Degim I.T., Ilbasmis S., Dundaroz R., Oguz Y. Reverse iontophoresis: a non-invasive technique for measuring blood urea level. Pediatr. Nephrol. 18:2003;1032-1037
5. Delgado-Charro M.B., Guy R.H. Transdermal reverse iontophoresis of valproate: a non-invasive method for therapeutic drug monitoring. Pharm. Res. 20:2003;1508-1513
6. Drobitch R.K., Svensson C.K. Therapeutic drug monitoring in saliva. An update. Clin. Pharmacokinet. 23:1992;365-379
7. Eadie M.J. Therapeutic drug monitoring - antiepileptic drugs. Br. J. Clin. Pharmacol. 46:1998;185-193
8. Gareri P., Gravina T., Ferreri G., De Sarro G. Treatment of epilepsy in the elderly. Prog. Neurobiol. 58:1999;389-407
9. Glikfeld P., Cullander C., Hinz R.S., Guy R.H. A new system for in vitro studies of iontophoresis. Pharm. Res. 5:1988;443-446
10. Glikfeld P., Hinz R.S., Guy R.H. Noninvasive sampling of biological fluids by iontophoresis. Pharm. Res. 6:1989;988-990
11. Green P.G., Hinz R.S., Cullander C., Yamane G., Guy R.H. Iontophoretic delivery of amino acids and amino acid derivatives across the skin in vitro. Pharm. Res. 8:1991;1113-1120
12. Kamali F., Thomas S.H.L. Effect of saliva flow rate on saliva phenytoin concentrations: implications for therapeutic monitoring. Eur. J. Clin. Pharmacol. 46:1994;565-567
13. Kodama H., Kodama Y., Shinozawa S., Kanemaru R., Tokada K., Mitsuyama Y. Serum protein binding kinetics of phenytoin in monotherapy patients. J. Clin. Pharm. Ther. 23:1998;361-365
14. Leboulanger B., Fathi M., Guy R.H., Delgado-Charro M.B. Reverse iontophoretic monitoring of lithium in vivo. Ther. Drug Monit. 25:2003;499
15. Leboulanger, B., Fathi, M., Guy, R.H., Delgado-Charro, M.B., 2004. Reverse iontophoresis as a non-invasive tool for lithium monitoring and pharmacokinetic profiling, Pharm. Res. 21, 1214-1222.
16. Merino V., Lopez A., Hochstrasser D., Guy R.H. Noninvasive sampling of phenylalanine by reverse iontophoresis. J. Control. Rel. 61:1999;65-69
17. Monks A., Boobis S., Wadsworth J., Richens A. Plasma protein binding interaction between phenytoin and valproic acid in vitro. Br. J. Clin. Pharmacol. 6:1978;487-492
18. Odar-Cederlöf I., Borga O. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid. Clin. Pharmacol. Ther. 20:1976;36-47
19. Parnas J., Flachs H., Gram L., Wuertz-Joergensen A. Excretion of antiepileptic drugs in sweat. Acta Neurol. Scand. 58:1978;197-204
20. Perucca E. Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. Ther. Drug Monit. 2:1980;331-344
21. Philip, J., Holcomb, I.J., Fusari, S.A., 1984. Phenytoin, in: Florey, K. (Eds.), Analytical Profiles of Drug Substances. Academic Press, San Diego, pp. 417-445.
22. Pichini S., Altieri I., Zuccaro P., Pacifici R. Drug monitoring in nonconventional biological fluids and matrices. Clin. Pharmacokinet. 30:1996;211-228
23. Pikal M.J., Shah S. Transport mechanisms in iontophoresis. III. An experimental study of the contributions of electroosmotic flow and permeability change in transport of low and high molecular weight solutes. Pharm. Res. 7:1990;222-231
24. Rao G., Glikfeld P., Guy R.H. Reverse iontophoresis: development of a non invasive approach for glucose monitoring. Pharm. Res. 10:1993;1751-1755
25. Rao G., Guy R.H., Glikfeld P., LaCourse W.R., Leung L., Tamada J., Potts R.O., Azimi N. Reverse iontophoresis: noninvasive glucose monitoring in vivo in humans. Pharm. Res. 12:1995;1869-1873
26. Sieg A., Guy R.H., Delgado-Charro M.B. Reverse iontophoresis for noninvasive glucose monitoring: The internal standard concept. J. Pharm. Sci. 92:2003;2295-2302
27. Suzuki Y., Mimaki T., Cox S., Koepke J., Hayes J., Walson P.D. Phenytoin age-dose-concentration relationship in children. Ther. Drug Monit. 16:1994;145-150
28. Warner A., Privitera M., Bates D. Standards of laboratory practice: antiepileptic drug monitoring. Clin. Chem. 44:1998;1085-1095